Elias Lazarides

Elias Lazarides is a prominent inventor based in La Jolla, CA (US). He has made significant contributions to the field of biotechnology, particularly in the development of therapeutic antibodies. With a total of 3 patents to his name, Lazarides continues to push the boundaries of medical science.

Latest Patents

Lazarides' latest patents include groundbreaking inventions such as anti-alpha2 integrin antibodies and their uses. This invention relates to humanized antibodies that bind to the I domain of alpha2 integrin, inhibiting its interaction with collagen. Additionally, he has developed therapeutic applications for these antibodies in treating alpha2beta1-mediated disorders. Another notable patent involves humanized antibodies specific for von Willebrand factor (vWF). This patent outlines methods for preparing these antibodies and their use in treating vWF-mediated diseases or disorders.

Career Highlights

Elias Lazarides is currently associated with Glenmark Pharmaceuticals S.A., where he applies his expertise in antibody development. His work has been instrumental in advancing therapeutic options for various medical conditions. His innovative approach and dedication to research have earned him recognition in the scientific community.

Collaborations

Lazarides collaborates with talented professionals in his field, including Catherine Mary Woods and Mark Bernard. These partnerships enhance the research and development process, leading to more effective therapeutic solutions.

Conclusion

Elias Lazarides exemplifies the spirit of innovation in biotechnology through his patents and collaborative efforts. His work continues to have a lasting impact on the medical field, paving the way for new treatments and therapies.

This text is generated by artificial intelligence and may not be accurate.